Skip to main content
. 2013 Jan 22;2013:194932. doi: 10.1155/2013/194932

Table 2.

Prevalence of HHV-6-DNA (copies/mL) and HHV-6-antibodies (U/mL) among different subtypes of MS. HHV-6-DNA was analyzed in serum via qPCR as described previously. Concentration of plasma anti-HHV-6, IgG and IgM were measurement in an automated instrument, according to the manufacturer's instructions. Data are representative of three independent experiments.

Saliva Serum PBMCs CSF Anti-IgG Anti-IgM
P (%)
[mean ± SD]
MS (n = 78)
 (1) RRMS (n = 46)
  CSF (n = 22)
6 (13.04)
[127 ± 12.43]
35 (76.08)
[272 ± 39.15]
36 (78.26)
[178 ± 42.60]
10 (45.45)
[128 ± 7.58]
38 (82.60)
[15.96 ± 1.43]
22 (47.82)
[24.85 ± 1.92]
 (2) SPMS (n = 11)
  CSF (n = 6)
3 (27.27)
[128 ± 9.84]
7 (63.63)
[294 ± 44.77]
7 (63.63)
[151 ± 14.44]
1 (16.66)
[145]
11 (100)
[16.51 ± 2.27]
4 (36.36)
[25.67 ± 1.43]
 (3) PPMS (n = 21)
  CSF (n = 10)
0 (—)
[—]
5 (23.80)
[165 ± 12.45]
9 (42.85)
[125 ± 7.23]
0 (—)
[—]
12 (57.14)
[13.32 ± 1.17]
1 (4.76)
[23.05]

Sig. (2-tailed)
 Subtypes (1), (2) NS NS P < 0.05 NS NS NS
 Subtypes (1), (3) P < 0.001 P < 0.001 P < 0.001 NS
 Subtypes (2), (3) P < 0.001 P < 0.001 P < 0.001 NS

PBMCs: peripheral blood mononuclear cells; CSF: cerebrospinal fluid; PPMS: primary progressive MS; RRMS: relapsing-remitting MS; SPMS: secondary progressive MS; P: positive; NS: not significant.